Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences Inc. is advancing its clinical-stage candidate PMN310, which is demonstrating a favorable safety profile, particularly regarding amyloid-related imaging abnormalities (ARIA), compared to existing marketed anti-amyloid therapies. The ongoing Phase Ib PRECISE-AD study has successfully achieved over 85% enrollment, indicating solid momentum towards clinical milestones, and the recent data show promise in preserving memory and learning in Alzheimer's disease mouse models. The Alzheimer's market presents a substantial commercial opportunity, reinforcing a positive outlook on the potential growth and market impact of ProMIS Neurosciences' innovative therapeutic approaches.

Bears say

ProMIS Neurosciences reported a significant net loss of $11.6 million for 3Q25, indicating ongoing financial strain as the company remains in a clinical stage without generating positive cash flow. The company faces multiple risks, including the potential inability to demonstrate the safety and efficacy of its lead candidate, PMN310, amidst high competition and market challenges, which could hinder its path to regulatory approval. Additionally, concerns regarding the need for future financing may exacerbate dilution risks for current shareholders, further contributing to the negative outlook on the stock.

PMN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 3 analysts, PMN has a Strong Buy consensus rating as of Mar 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.